Dr. Reddy's Q1 Review - India Leads Growth, U.S. Disappoints: Prabhudas Lilladher
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Prabhudas Lilladher Report
We reduced Dr. Reddy's Laboratories Ltd.'s earnings estimates by 20% and 10% in FY22E and FY23E respectively, due to steep price erosion in molecules launched in last 12 months and higher overhead costs (mainly promotional expenses of oil-to-chemical and new brands from Wockhardt).
However, we maintained our earnings estimates for key molecules in pipeline (gCopaxone, gVascepa and gNuvaring) along with option value of gRevlimid in FY22E-23E.
We expect Dr. Reddy's to launch gCopaxone now in Q4 FY22E (versus earlier expectation of H1 FY22E), and the launch of gNuvaring depends on faster resolution of pending complete response letter.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.